Topic Highlight
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Orthop. Oct 18, 2013; 4(4): 207-217
Published online Oct 18, 2013. doi: 10.5312/wjo.v4.i4.207
RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases
Hisataka Yasuda
Hisataka Yasuda, Bioindustry Division, Oriental Yeast Co., Ltd., Tokyo 174-8505, Japan
Author contributions: Yasuda H solely contributed to this paper.
Correspondence to: Hisataka Yasuda, PhD, Bioindustry Division, Oriental Yeast Co., Ltd., 3-6-10 Azusawa, Itabashi-ku, Tokyo 174-8505, Japan.
Telephone: +81-3-39681192 Fax: +81-3-39684863
Received: January 7, 2013
Revised: May 21, 2013
Accepted: June 19, 2013
Published online: October 18, 2013
Core Tip

Core tip: This review describes a success story from discovery of osteoprotegerin/receptor activator of nuclear factor-κB ligand (RANKL)/receptor activator of nuclear factor-κB (RANK) to clinical application of a fully human anti-RANKL monoclonal antibody to the treatment of osteoporosis and cancer-related bone disorders. RANKL is a key molecule for osteoclast differentiation and activation. Inhibition of RANKL activity with anti-RANKL antibody reduces osteoclastogenesis, resulting in inhibition of bone resorption. Three animal disease models of osteoporosis, hypercalcemia, and osteopetrosis by treating normal mice with soluble RANKL (sRANKL), adenovirus expressing sRANKL, and anti-mouse RANKL neutralizing antibody, respectively, can be established in 2-14 d and the establishment of these animal models could help accelerate research on bone metabolism.